Novo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal ...

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small ...

Reflecting on 20 years of experience working as a scientist in Big Pharma and biotech, Louise Modis, Ph.D., CSO at Amphista ...

The Biden administration, through policy and leadership appointments, raised the level of government scrutiny over ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

Following a years-long Big Pharma retreat from the discovery and development of new drugs for psychiatric and mental health disorders, an expanding group of psychedelic drug developers -- and ...